Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florian Heitz

Showing results (71-80 of 178) with videos related to

Pageof 18
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 2, 2020
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)Philipp Harter, Patricia Pautier, Els Van Nieuwenhuysen, et al.
British Journal of Cancer|December 19, 2021
Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC)Christina Fotopoulou, Andrea Rockall, Haonan Lu, et al.
Gynecologic Oncology|December 4, 2019
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancerIgnace Vergote, Florian Heitz, Paul Buderath, et al.
Cancers|January 11, 2022
Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer-Impact for Diagnosis and Treatment MonitoringElena Ioana Braicu, Andreas du Bois, Jalid Sehouli, et al.
Annals of Surgical Oncology|August 3, 2018
Skeletal Muscle Attenuation (Sarcopenia) Predicts Reduced Overall Survival in Patients with Advanced Epithelial Ovarian Cancer Undergoing Primary Debulking SurgeryBeyhan Ataseven, Teresa González Luengo, Andreas du Bois, et al.
Journal of Surgical Oncology|March 28, 2023
Treatment and survival of patients with malignant ovarian sex cord-stromal cell tumours: An analysis of the Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) study group CORSETT databaseMaximilian Klar, Helmut Plett, Philipp Harter, et al.
Archives of Gynecology and Obstetrics|July 21, 2021
The effect of fertility-sparing surgery on sexuality and global quality of life in women with malignant ovarian germ cell and sex cord stromal tumors: an analysis of the CORSETT database of the AGO study groupAnnette Hasenburg, Hellmut Plett, Bernhard Krämer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 7, 2023
AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trialFlorian Heitz, Christian Marth, Stéphanie Henry, et al.
Annals of Surgical Oncology|June 14, 2017
Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter StudyLucas Minig, Florian Heitz, David Cibula, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2023
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancerAntonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
Pageof 18

Showing results (71-80 of 178) with videos related to

Sort By:
Pageof 18
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 2, 2020
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)Philipp Harter, Patricia Pautier, Els Van Nieuwenhuysen, et al.
British Journal of Cancer|December 19, 2021
Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC)Christina Fotopoulou, Andrea Rockall, Haonan Lu, et al.
Gynecologic Oncology|December 4, 2019
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancerIgnace Vergote, Florian Heitz, Paul Buderath, et al.
Cancers|January 11, 2022
Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer-Impact for Diagnosis and Treatment MonitoringElena Ioana Braicu, Andreas du Bois, Jalid Sehouli, et al.
Annals of Surgical Oncology|August 3, 2018
Skeletal Muscle Attenuation (Sarcopenia) Predicts Reduced Overall Survival in Patients with Advanced Epithelial Ovarian Cancer Undergoing Primary Debulking SurgeryBeyhan Ataseven, Teresa González Luengo, Andreas du Bois, et al.
Journal of Surgical Oncology|March 28, 2023
Treatment and survival of patients with malignant ovarian sex cord-stromal cell tumours: An analysis of the Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) study group CORSETT databaseMaximilian Klar, Helmut Plett, Philipp Harter, et al.
Archives of Gynecology and Obstetrics|July 21, 2021
The effect of fertility-sparing surgery on sexuality and global quality of life in women with malignant ovarian germ cell and sex cord stromal tumors: an analysis of the CORSETT database of the AGO study groupAnnette Hasenburg, Hellmut Plett, Bernhard Krämer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 7, 2023
AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trialFlorian Heitz, Christian Marth, Stéphanie Henry, et al.
Annals of Surgical Oncology|June 14, 2017
Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter StudyLucas Minig, Florian Heitz, David Cibula, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2023
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancerAntonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
Pageof 18